Boceprevir and Treatment of Chronic Hepatitis C

Paul Y. Kwo

Research output: Contribution to journalReview article

4 Scopus citations


The addition of boceprevir to peginterferon and ribavirin has improved sustained response rates markedly. Boceprevir is effective in treatment naïve, relapsers, partial responders, and null responders. Those with advanced fibrosis require 44 weeks of boceprevir therapy after a 4-week peg/ribavirin lead-in. The main side effect with boceprevir is anemia and ribavirin dose reduction is an effective strategy. This review examines the current treatment paradigm of boceprevir-based treatment of chronic hepatitis C, examining treatment paradigms, predictors of response, futility rules, as well as preliminary results from studies examining boceprevir efficacy in additional populations. Further follow-up in these cohorts will be required.

Original languageEnglish (US)
Pages (from-to)63-72
Number of pages10
JournalClinics in Liver Disease
Issue number1
StatePublished - Feb 1 2013


  • Boceprevir
  • Hepatitis C
  • Peginterferon
  • Ribavirin

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Boceprevir and Treatment of Chronic Hepatitis C'. Together they form a unique fingerprint.

  • Cite this